4basebio PLC (AIM:4BB)
London · Delayed Price · Currency is GBP · Price in GBX 550.00
0.00 (0.00%)
Aug 14, 2026, 4:35 PM GMT
4basebio Market Cap
4basebio has a market cap or net worth of 85.46 million as of August 14, 2026. Its market cap has decreased by -38.65% in one year.
Market Cap
85.46M
Enterprise Value
84.14M
Revenue
1.69M
Ranking
n/a
PE Ratio
n/a
Stock Price
550.00
ChartMarket Cap Chart
Since February 17, 2021, 4basebio's market cap has increased from 41.57M to 85.46M, an increase of 105.58%. That is a compound annual growth rate of 14.03%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 14, 2026 | 85.46M | -10.22% |
| Dec 31, 2025 | 95.19M | -38.57% |
| Dec 31, 2024 | 154.94M | 84.96% |
| Dec 29, 2023 | 83.77M | -4.21% |
| Dec 30, 2022 | 87.45M | 15.45% |
| Dec 31, 2021 | 75.75M | 82.22% |
| Feb 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| PureTech Health | 289.18M |
| Scancell Holdings | 116.37M |
| Faron Pharmaceuticals Oy | 88.84M |
| Bioventix | 78.37M |
| Ondine Biomedical | 71.44M |
| Poolbeg Pharma | 64.89M |
| hVIVO | 45.00M |
| Hemogenyx Pharmaceuticals | 41.17M |